ShangBay Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 4
- Investments
- 61
- Portfolio
- 46
- Exits
- 8
ShangBay Capital General Information
Description
Founded in 2015, ShangBay Capital is a venture capital firm headquartered in Palo Alto, California. The firm seeks to invest in the life sciences, medical device, biotechnology, and mobile healthcare sectors.
Contact Information
Website
www.shangbaycapital.com
Year Founded
2015
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- 1555 Alma Street
- Palo Alto, CA 94301
- United States
ShangBay Capital Investments (61)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Huma.AI | 10-Feb-2022 | Later Stage VC | 00.00 | Other Healthcare Technology Systems | Generating Revenue | 0000000 000 |
| 0000000 0000000000 | 09-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | |
| 0000000 0000000 | 12-Nov-2021 | 0000 00000 | 00.000 | Therapeutic Devices | Pre-Clinical Trials | |
| 0000000 | 08-Nov-2021 | 00000 00000 | 0000 | Diagnostic Equipment | Generating Revenue | 0000000 000 |
| 0000000000 | 20-Oct-2021 | 00000 00000 | 000.00 | Other Pharmaceuticals and Biotechnology | Clinical Trials - General | |
| 0000000 00000000 | 17-Oct-2021 | 00000 00000 | 000 | Surgical Devices | Generating Revenue | |
| 00000 0000000 | 01-Oct-2021 | 00000 00000 | Other Healthcare Technology Systems | Stealth | ||
| 0000000 0000000000 | 01-Sep-2021 | 00000 00000 | 00.00 | Therapeutic Devices | Product Development | 0000000 000 |
| Neuro42 | 27-Jul-2021 | Early Stage VC | 00.00 | Diagnostic Equipment | Startup | |
| IgGenix | 26-Jul-2021 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue |
ShangBay Capital Exits (8)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Qool Therapeutics | 12-Oct-2021 | Out of Business | |
| 000000 00000000000 | 15-Sep-2021 | 0000000000: 000000 | |
| 000000 000000 | 05-Feb-2021 | 000 | 00000 |
| 00000000 000000 | 17-Jul-2020 | 000 | 00000 |
| 0000000000 | 09-Jan-2020 | 0000000000 | 0000 |
| Arrinex | 25-Feb-2019 | Merger/Acquisition | 00000 |
| NeuroVasc Technologies | Secondary Transaction - Private |
ShangBay Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialShangBay Capital Team (10)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| William Dai | Founding Managing Partner | 00 | 0 | 0 | Palo Alto, CA |
| Chaucer Shen MD | Managing Partner | 0 | 0 | 0 | Palo Alto, CA |
| Andy Weimin Dai | Senior Advisor | Palo Alto, CA | |||
| Mel Dong Ph.D | Senior Advisor | Palo Alto, CA | |||
| Andrew Chen | Senior Associate | Palo Alto, CA |
ShangBay Capital Co-Investors (179)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| SV Tech Ventures | 5 | 0 | 0 |
|
|
| Aethan Capital | 0 | 0 |
|
|
|
| 3E Bioventures Capital | 0 | 0 |
|
|
|
| MBX Capital | 0 | 0 | 0 |
|
|
| ShangPharma Innovation | 0 |
|
|